PCRX up +1.87% percent Today $PCRX High is at 88.7
Post# of 46
Posted On: 11/10/2014 1:21:16 PM
PCRX up +1.87% percent Today $PCRX High is at 88.73 and the Low 85.84 with current volume of 154,790.
Recent News posted below.
Pacira Pharmaceuticals PCRX other info.
http://investorshangout.com/Pacira-Pharmaceut...CRX-55067/
PCRX Pacira Pharmaceuticals Recent Headline News
Pacira Pharmaceuticals Inc. Announces New Data on the Use of EXPAREL to Treat Postsurgical Pain Following Total Knee Arthroplasty
Business Wire - Thu Nov 06, 3:00PM CST
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results of an independent, physician-initiated study designed to evaluate the difference in postsurgical pain and opioid consumption between patients who received EXPAREL versus a multi-drug analgesic cocktail for pain management following total knee arthroplasty (TKA). The data, presented at the annual meeting of the American Association of Hip and Knee Surgeons (AAHKS), found that patients treated with EXPAREL reported significantly lower patient-perceived pain scores and morphine sulfate equivalence consumption, and reported higher satisfaction with pain control and overall experience, compared with patients who received the multi-drug analgesic cocktail. The meeting is being held Nov. 6-9 at the Sheraton Dallas Hotel.
PCRX: 87.83 (+1.81)
Quarterly Financial Results and Product Approval - Research Reports on Pacira, PAREXEL, WellPoint, Illumina and St. Jude Medical
PR Newswire - Tue Nov 04, 8:00AM CST
Today, Analysts Review released its research reports regarding Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), PAREXEL International Corporation (NASDAQ: PRXL), WellPoint Inc. (NYSE: WLP), Illumina, Inc. (NASDAQ: ILMN) and St. Jude Medical, Inc. (NYSE: STJ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7670-100free.
PRXL: 54.25 (+0.28), STJ: 65.19 (+0.43), ILMN: 188.80 (+2.45), PCRX: 87.83 (+1.81), WLP: 125.50 (+1.35)
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Pacira Pharmaceuticals, Inc. and Certain Officers - PCRX
PR Newswire - Fri Oct 31, 2:07PM CDT
Pomerantz LLP has filed a class action lawsuit against Pacira Pharmaceuticals, Inc. ("Pacira" or the "Company"
(NASDAQ: PCRX) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 14-cv-06172, is on behalf of a class consisting of all persons or entities who purchased Pacira securities between April 9, 2012 and September 24, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" .
PCRX: 87.83 (+1.81)
Pacira Down on Wider than Expected Q3 Loss, Sales Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 12:00PM CDT
Pacira Pharmaceuticals' (PCRX) third-quarter 2014 loss of 5 cents per share was wider than the Zacks Consensus Estimate of a loss of a penny but much narrower than the year-ago loss of 41 cents per share.
LCI: 51.15 (+0.98), VRX: 127.88 (+1.77), AUXL: 32.74 (-0.01), PCRX: 87.83 (+1.81)
Today's Dead Cat Bounce Stock: Pacira Pharmaceuticals (PCRX)
at The Street - Fri Oct 31, 8:50AM CDT
Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a "dead cat bounce" (down big yesterday but up big today) candidate
PCRX: 87.83 (+1.81)
Nasdaq stocks posting largest percentage decreases
AP - Thu Oct 30, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
BBOX: 23.27 (-0.57), AFOP: 13.55 (+0.05), AMCC: 6.38 (-0.08), NSIT: 23.09 (+0.09), ARAY: 6.85 (unch), HTWR: 77.20 (+0.66), CCUR: 7.07 (+0.09), THRM: 40.52 (-0.38), RPXC: 13.79 (-0.14), BWEN: 6.71 (+0.07), PRXL: 54.25 (+0.28), AZPN: 37.70 (+0.11), BBSI: 23.97 (-1.26), CRUS: 19.66 (+0.11), ARCP: 8.62 (-0.17), PCRX: 87.83 (+1.81), XOOM: 14.63 (-0.07)
Pacira posts 3Q loss
Automated Insights - Thu Oct 30, 5:48AM CDT
PARSIPPANY, N.J. (AP) _ Pacira Pharmaceuticals Inc. (PCRX) on Thursday reported a loss of $3 million in its third quarter.
PCRX: 87.83 (+1.81)
Pacira Pharmaceuticals, Inc. Reports Third Quarter EXPAREL Revenue of $50.2 Million and Third Quarter 2014 Results
Business Wire - Thu Oct 30, 5:30AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on the success of EXPAREL(R) (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the third quarter ended September 30, 2014.
PCRX: 87.83 (+1.81)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Pacira Pharmaceuticals, Inc. to Contact Brower Piven Before the December 2, 2014 Lead Plaintiff Deadline in Class Action Lawsuit -- PCRX
GlobeNewswire - Wed Oct 29, 12:19PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Pacira Pharmaceuticals, Inc. ("Pacira" or the "Company" (Nasdaq
CRX) securities during the period between April 9, 2012 and September 24, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until December 2, 2014 to seek appointment as lead plaintiff.
PCRX: 87.83 (+1.81)
New Study Correlates Use of EXPAREL for Postsurgical Pain Management with Significant Reductions in Opioid Related Adverse Events
Business Wire - Mon Oct 27, 3:00PM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results of an independent, physician-initiated study that reinforce the positive impact of an EXPAREL-based pain management regimen on reducing postsurgical complications associated with opioid use. The data, presented at the American College of Surgeons (ACS) Clinical Congress, found that patients treated with EXPAREL experienced statistically significantly lower rates of urinary retention, respiratory depression and fall risk compared to their counterparts who received the previous standard of care (SOC). The ACS Clinical Congress is being held October 26-30 at the Moscone Center in San Francisco.
PCRX: 87.83 (+1.81)
Valeant (VRX) Beats Earnings Estimates in Q3, Shares Gain - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 23, 8:05AM CDT
Shares of Valeant Pharmaceuticals (VRX) gained 3.1% immediately after the company reported its third-quarter 2014 results.
AGN: 195.26 (-0.74), LCI: 51.15 (+0.98), VRX: 127.88 (+1.77), PCRX: 87.83 (+1.81)
EQUITY ALERT: Rosen Law Firm Reminds Pacira Pharmaceuticals, Inc. Investors of Important Class Action Deadline -- PCRX
GlobeNewswire - Wed Oct 22, 1:47PM CDT
Rosen Law Firm reminds purchasers of Pacira Pharmaceuticals, Inc. stock (Nasdaq CRX) during the period from April 9, 2012 through September 24, 2014, of the important December 2, 2014 lead plaintiff deadline in the class action.
PCRX: 87.83 (+1.81)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Pacira Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 2, 2014 -- PCRX
GlobeNewswire - Tue Oct 21, 11:46AM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Pacira Pharmaceuticals, Inc. ("Pacira" or the "Company" (Nasdaq CRX) stock between April 9, 2012 and September 24, 2014.
PCRX: 87.83 (+1.81)
Astellas Files for Amendment of Isavuconazole Study Protocol - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 4:15PM CDT
Astellas Pharma, Inc. (ALPMY) submitted an amendment for its phase III study (ACTIVE) protocol on isavuconazole for invasive fungal infections.
LCI: 51.15 (+0.98), SHPG: 200.23 (+1.65), PCRX: 87.83 (+1.81)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Pacira Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline -- PCRX
GlobeNewswire - Fri Oct 17, 12:46PM CDT
Pomerantz LLP has filed a class action lawsuit against Pacira Pharmaceuticals, Inc. ("Pacira" or the "Company" (Nasdaq CRX) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 14-cv-06172, is on behalf of a class consisting of all persons or entities who purchased Pacira securities between April 9, 2012 and September 24, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" .
PCRX: 87.83 (+1.81)
Pacira Pharmaceuticals (PCRX): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 7:45AM CDT
Pacira Pharmaceuticals is one stock that might be an intriguing choice for investors as it is seeing solid earnings estimate revision and has Zacks Industry Rank of 74
PCRX: 87.83 (+1.81)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Pacira Pharmaceuticals, Inc. To Contact Brower Piven Before The December 2, 2014 Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Wed Oct 15, 5:26PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Pacira Pharmaceuticals, Inc. ("Pacira" or the "Company" (NASDAQ: PCRX) securities during the period between April 9, 2012 and September 24, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until December 2, 2014 to seek appointment as lead plaintiff.
PCRX: 87.83 (+1.81)
Sucampo/Takeda Amend Collaboration Agreement for Amitiza - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 5:07PM CDT
Sucampo Pharmaceuticals, Inc. (SCMP) announced that it has amended its existing collaboration and license agreement with Takeda Pharmaceutical Company Ltd.
LCI: 51.15 (+0.98), SHPG: 200.23 (+1.65), SCMP: 9.49 (+0.24), PCRX: 87.83 (+1.81)
Pacira Pharmaceuticals Announces Timing for Third Quarter 2014 Financial Results Webcast and Conference Call
Business Wire - Wed Oct 15, 5:30AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ CRX) today announced that financial results for the company's third quarter ended September 30, 2014, will be released before the market opens on Thursday, October 30, 2014. The Pacira management team will host a conference call to discuss the company's financial results and recent and upcoming developments on Thursday, October 30, 2014, at 9 a.m. ET. The call can be accessed by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international) fifteen minutes prior to the start of the call and providing the Conference ID 2794612.
PCRX: 87.83 (+1.81)
Recent News posted below.
Pacira Pharmaceuticals PCRX other info.
http://investorshangout.com/Pacira-Pharmaceut...CRX-55067/
PCRX Pacira Pharmaceuticals Recent Headline News
Pacira Pharmaceuticals Inc. Announces New Data on the Use of EXPAREL to Treat Postsurgical Pain Following Total Knee Arthroplasty
Business Wire - Thu Nov 06, 3:00PM CST
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results of an independent, physician-initiated study designed to evaluate the difference in postsurgical pain and opioid consumption between patients who received EXPAREL versus a multi-drug analgesic cocktail for pain management following total knee arthroplasty (TKA). The data, presented at the annual meeting of the American Association of Hip and Knee Surgeons (AAHKS), found that patients treated with EXPAREL reported significantly lower patient-perceived pain scores and morphine sulfate equivalence consumption, and reported higher satisfaction with pain control and overall experience, compared with patients who received the multi-drug analgesic cocktail. The meeting is being held Nov. 6-9 at the Sheraton Dallas Hotel.
PCRX: 87.83 (+1.81)
Quarterly Financial Results and Product Approval - Research Reports on Pacira, PAREXEL, WellPoint, Illumina and St. Jude Medical
PR Newswire - Tue Nov 04, 8:00AM CST
Today, Analysts Review released its research reports regarding Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), PAREXEL International Corporation (NASDAQ: PRXL), WellPoint Inc. (NYSE: WLP), Illumina, Inc. (NASDAQ: ILMN) and St. Jude Medical, Inc. (NYSE: STJ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7670-100free.
PRXL: 54.25 (+0.28), STJ: 65.19 (+0.43), ILMN: 188.80 (+2.45), PCRX: 87.83 (+1.81), WLP: 125.50 (+1.35)
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Pacira Pharmaceuticals, Inc. and Certain Officers - PCRX
PR Newswire - Fri Oct 31, 2:07PM CDT
Pomerantz LLP has filed a class action lawsuit against Pacira Pharmaceuticals, Inc. ("Pacira" or the "Company"
(NASDAQ: PCRX) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 14-cv-06172, is on behalf of a class consisting of all persons or entities who purchased Pacira securities between April 9, 2012 and September 24, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" . PCRX: 87.83 (+1.81)
Pacira Down on Wider than Expected Q3 Loss, Sales Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 12:00PM CDT
Pacira Pharmaceuticals' (PCRX) third-quarter 2014 loss of 5 cents per share was wider than the Zacks Consensus Estimate of a loss of a penny but much narrower than the year-ago loss of 41 cents per share.
LCI: 51.15 (+0.98), VRX: 127.88 (+1.77), AUXL: 32.74 (-0.01), PCRX: 87.83 (+1.81)
Today's Dead Cat Bounce Stock: Pacira Pharmaceuticals (PCRX)
at The Street - Fri Oct 31, 8:50AM CDT
Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a "dead cat bounce" (down big yesterday but up big today) candidate
PCRX: 87.83 (+1.81)
Nasdaq stocks posting largest percentage decreases
AP - Thu Oct 30, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
BBOX: 23.27 (-0.57), AFOP: 13.55 (+0.05), AMCC: 6.38 (-0.08), NSIT: 23.09 (+0.09), ARAY: 6.85 (unch), HTWR: 77.20 (+0.66), CCUR: 7.07 (+0.09), THRM: 40.52 (-0.38), RPXC: 13.79 (-0.14), BWEN: 6.71 (+0.07), PRXL: 54.25 (+0.28), AZPN: 37.70 (+0.11), BBSI: 23.97 (-1.26), CRUS: 19.66 (+0.11), ARCP: 8.62 (-0.17), PCRX: 87.83 (+1.81), XOOM: 14.63 (-0.07)
Pacira posts 3Q loss
Automated Insights - Thu Oct 30, 5:48AM CDT
PARSIPPANY, N.J. (AP) _ Pacira Pharmaceuticals Inc. (PCRX) on Thursday reported a loss of $3 million in its third quarter.
PCRX: 87.83 (+1.81)
Pacira Pharmaceuticals, Inc. Reports Third Quarter EXPAREL Revenue of $50.2 Million and Third Quarter 2014 Results
Business Wire - Thu Oct 30, 5:30AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on the success of EXPAREL(R) (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the third quarter ended September 30, 2014.
PCRX: 87.83 (+1.81)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Pacira Pharmaceuticals, Inc. to Contact Brower Piven Before the December 2, 2014 Lead Plaintiff Deadline in Class Action Lawsuit -- PCRX
GlobeNewswire - Wed Oct 29, 12:19PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Pacira Pharmaceuticals, Inc. ("Pacira" or the "Company"
(Nasdaq CRX) securities during the period between April 9, 2012 and September 24, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until December 2, 2014 to seek appointment as lead plaintiff. PCRX: 87.83 (+1.81)
New Study Correlates Use of EXPAREL for Postsurgical Pain Management with Significant Reductions in Opioid Related Adverse Events
Business Wire - Mon Oct 27, 3:00PM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results of an independent, physician-initiated study that reinforce the positive impact of an EXPAREL-based pain management regimen on reducing postsurgical complications associated with opioid use. The data, presented at the American College of Surgeons (ACS) Clinical Congress, found that patients treated with EXPAREL experienced statistically significantly lower rates of urinary retention, respiratory depression and fall risk compared to their counterparts who received the previous standard of care (SOC). The ACS Clinical Congress is being held October 26-30 at the Moscone Center in San Francisco.
PCRX: 87.83 (+1.81)
Valeant (VRX) Beats Earnings Estimates in Q3, Shares Gain - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 23, 8:05AM CDT
Shares of Valeant Pharmaceuticals (VRX) gained 3.1% immediately after the company reported its third-quarter 2014 results.
AGN: 195.26 (-0.74), LCI: 51.15 (+0.98), VRX: 127.88 (+1.77), PCRX: 87.83 (+1.81)
EQUITY ALERT: Rosen Law Firm Reminds Pacira Pharmaceuticals, Inc. Investors of Important Class Action Deadline -- PCRX
GlobeNewswire - Wed Oct 22, 1:47PM CDT
Rosen Law Firm reminds purchasers of Pacira Pharmaceuticals, Inc. stock (Nasdaq
CRX) during the period from April 9, 2012 through September 24, 2014, of the important December 2, 2014 lead plaintiff deadline in the class action. PCRX: 87.83 (+1.81)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Pacira Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 2, 2014 -- PCRX
GlobeNewswire - Tue Oct 21, 11:46AM CDT
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Pacira Pharmaceuticals, Inc. ("Pacira" or the "Company"
(Nasdaq CRX) stock between April 9, 2012 and September 24, 2014. PCRX: 87.83 (+1.81)
Astellas Files for Amendment of Isavuconazole Study Protocol - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 4:15PM CDT
Astellas Pharma, Inc. (ALPMY) submitted an amendment for its phase III study (ACTIVE) protocol on isavuconazole for invasive fungal infections.
LCI: 51.15 (+0.98), SHPG: 200.23 (+1.65), PCRX: 87.83 (+1.81)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Pacira Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline -- PCRX
GlobeNewswire - Fri Oct 17, 12:46PM CDT
Pomerantz LLP has filed a class action lawsuit against Pacira Pharmaceuticals, Inc. ("Pacira" or the "Company"
(Nasdaq CRX) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 14-cv-06172, is on behalf of a class consisting of all persons or entities who purchased Pacira securities between April 9, 2012 and September 24, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" . PCRX: 87.83 (+1.81)
Pacira Pharmaceuticals (PCRX): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 7:45AM CDT
Pacira Pharmaceuticals is one stock that might be an intriguing choice for investors as it is seeing solid earnings estimate revision and has Zacks Industry Rank of 74
PCRX: 87.83 (+1.81)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Pacira Pharmaceuticals, Inc. To Contact Brower Piven Before The December 2, 2014 Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Wed Oct 15, 5:26PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Pacira Pharmaceuticals, Inc. ("Pacira" or the "Company"
(NASDAQ: PCRX) securities during the period between April 9, 2012 and September 24, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until December 2, 2014 to seek appointment as lead plaintiff. PCRX: 87.83 (+1.81)
Sucampo/Takeda Amend Collaboration Agreement for Amitiza - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 5:07PM CDT
Sucampo Pharmaceuticals, Inc. (SCMP) announced that it has amended its existing collaboration and license agreement with Takeda Pharmaceutical Company Ltd.
LCI: 51.15 (+0.98), SHPG: 200.23 (+1.65), SCMP: 9.49 (+0.24), PCRX: 87.83 (+1.81)
Pacira Pharmaceuticals Announces Timing for Third Quarter 2014 Financial Results Webcast and Conference Call
Business Wire - Wed Oct 15, 5:30AM CDT
Pacira Pharmaceuticals, Inc. (NASDAQ
CRX) today announced that financial results for the company's third quarter ended September 30, 2014, will be released before the market opens on Thursday, October 30, 2014. The Pacira management team will host a conference call to discuss the company's financial results and recent and upcoming developments on Thursday, October 30, 2014, at 9 a.m. ET. The call can be accessed by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international) fifteen minutes prior to the start of the call and providing the Conference ID 2794612. PCRX: 87.83 (+1.81)
(0)
(0)